Results 271 to 279 of about 85,285 (279)
Some of the next articles are maybe not open access.
Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors
Drug and Therapeutics Bulletin, 2023After initially being licensed as treatment for diabetes, the range of indications for sodium-glucose co-transporter 2 (SGLT2) inhibitors has expanded to include chronic heart failure and chronic kidney disease. This article provides an overview of some of the evidence that supports the use of SGLT2 inhibitors in the management of chronic heart failure
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy
Expert Review of Endocrinology & Metabolism, 2015Type 2 diabetes effects millions of people yet remains difficult to treat with oral pharmacotherapy. Metformin is the first line recommended therapy, and current guidelines suggest individualized therapy for second line selection. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the newest class of agents in treating type 2 diabetes via an ...
Molly G, Minze +4 more
openaire +2 more sources
Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
Journal of the American Society of Hypertension, 2014Management of hypertension in diabetes is critical for reduction of cardiovascular mortality and morbidity. While blood pressure (BP) control has improved over the past two decades, the control rate is still well below 50% in the general population of patients with type 2 diabetes mellitus (T2DM).
Raymond V, Oliva, George L, Bakris
openaire +2 more sources
Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors: New among Antidiabetic Drugs
Cardiovascular Drugs and Therapy, 2014Type 2 diabetes is characterized by decreased insulin secretion and sensitivity. The available oral anti-diabetic drugs act on many different molecular sites. The most used of oral anti-diabetic agents is metformin that activates glucose transport vesicles to the cell surface.
openaire +2 more sources
[Sodium-glucose co-transporter 2 inhibitor for diabetes?].
Nederlands tijdschrift voor geneeskunde, 2016Following initial expectations, raised by the results of the United Kingdom Prospective Diabetes Study, intervention studies aimed at tight glucose control did not reduce cardiovascular disease. The EMPA-REG OUTCOME, an empagliflozin intervention study in over 7,000 patients with type 2 diabetes mellitus and a history of cardiovascular disease, for the
openaire +1 more source
วัตถุประสงค์: เพื่อหาปัจจัยนำ (Predisposing factors) ที่สัมพันธ์กับการเกิดภาวะกรดคั่งในเลือดจากสารคีโตน (Diabetic ketoacidosis; DKA) ในผู้ป่วยชาวไทยโรคเบาหวานชนิดที่ 2 ที่ใช้ยาในกลุ่ม Sodium glucose co-transporter 2 inhibitors (SGLT-2 inhibitors) วิธีการศึกษา: งานวิจัยนี้เป็นการศึกษาจากผลไปหาเหตุแบบเก็บข้อมูลย้อนหลังในหลายศูนย์ รวบรวมข้อมูลผู้ป ...
openaire +1 more source
openaire +1 more source
Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure
The American Journal of Cardiology, 2020Erkan Cure, Medine Cumhur Cure
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitor associated normoglycaemic ketoacidosis
Endocrine Abstracts, 2015Shane Bobart +5 more
openaire +1 more source
Sodium Glucose Co-Transporter 2 Inhibitor Use Post-Transplant
The Journal of Heart and Lung TransplantationJ. Nickol +5 more
openaire +1 more source